Coeptis Announces Nasdaq Approval for Z Squared Merger—Details for Investors
Coeptis Therapeutics Receives Nasdaq Approval for Z Squared Merger: Key Investor Takeaways
Major Milestone Reached in Pending Merger with Z Squared Inc.
Wexford, PA, April 7, 2026 – Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP), a next-generation technology and biopharmaceutical company, announced a significant milestone in its pending merger with Z Squared Inc. Nasdaq has conditionally approved, subject to customary closing requirements, the listing of the post-merger company’s common stock on the Nasdaq Global Market under the new ticker symbol “ZSQR”. The transition to the new ticker will become effective upon the successful closing of the merger transaction.
Key Points Investors Should Note
-
Nasdaq Listing Approval: This approval is a critical closing condition for the merger and signals regulatory confidence in the combined entity’s prospects.
-
Post-Merger Structure: Upon closing, Z Squared will become a wholly owned subsidiary of Coeptis, and the corporate name will change to Z Squared Inc.
-
Ticker Symbol Change: The company will trade under “ZSQR” following the merger, replacing “COEP.”
-
Expected Timeline: The merger is anticipated to close in Q2 2026, assuming all remaining conditions are met.
-
Shareholder Approvals: The deal has already received shareholder approval and the effectiveness of the registration statement (Form S-4, File No. 333-288329) has been confirmed.
Why This Is Price Sensitive
-
Potential Re-rating Event: The approval of the Nasdaq listing and the impending merger completion are both major catalysts for a re-rating of the company’s share price.
-
Strategic Shift: The merger will transform Coeptis from a traditional biopharmaceutical and technology company into the largest publicly traded pure-play Dogecoin (DOGE) miner in the United States, opening new revenue streams and investor appeal.
-
Operational Scale: Z Squared plans to deploy 9,800 ASIC miners across North Carolina, South Carolina, and Iowa, establishing itself as a leader in institutional-scale crypto mining for Dogecoin and Litecoin.
-
Disciplined Approach: Z Squared’s business model focuses on converting mined assets to USD or stablecoins within 24 hours, emphasizing cash flow over speculative asset holding—potentially reducing risk and providing more predictable financial outcomes.
-
Regulatory Compliance: Coeptis continues to operate within FDA regulatory frameworks for its biopharmaceutical business, ensuring high compliance and patient care standards.
Business Overview: Coeptis and Z Squared
About Coeptis
Coeptis operates across several fronts:
-
Biopharmaceutical Division: Focused on innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, including assets licensed from Deverra Therapeutics (allogeneic cellular immunotherapy and DVX201, a clinical-stage NK cell therapy).
-
Technology Division: Recently established, this unit leverages AI-powered marketing software and robotic process automation tools acquired from NexGenAI Solutions Group to optimize business processes and efficiency.
-
Collaborative Research: Active partnerships include the University of Pittsburgh (SNAP-CAR universal CAR technology) and the Karolinska Institute for GEAR cell therapy.
The company is headquartered in Wexford, PA, and maintains a strong commitment to regulatory compliance and patient outcomes.
About Z Squared
Z Squared is a digital infrastructure company focused on large-scale mining for the Dogecoin and Litecoin networks. The company’s disciplined operational model includes rapid conversion of mined assets to cash or stablecoins, rather than holding cryptocurrencies on the balance sheet.
-
Facilities: Mining operations are distributed across North Carolina, South Carolina, and Iowa.
-
Scale: 9,800 ASIC miners to be deployed, making it the largest publicly traded Dogecoin miner in the U.S.
-
Management: Led by a team with deep expertise in crypto mining and infrastructure management.
Other Shareholder Considerations
-
Customary Closing Conditions: The transaction still requires satisfaction of remaining customary conditions. There is no absolute assurance the deal will close, though expectations point to Q2 2026.
-
Forward-Looking Statements: The company cautions that statements regarding future plans, performance, and expectations are subject to risk and uncertainty. Investors should not place undue reliance on these statements, as actual results may differ.
-
Regulatory Filings: Detailed information regarding the merger, the interests of directors and officers, and associated risks are available in the company’s filings with the SEC.
Investor Relations Contacts
Disclaimer
This article is for informational purposes only and does not constitute investment advice, an offer to sell, or a solicitation of an offer to buy any securities. All forward-looking statements are subject to risks and uncertainties as discussed in company filings with the SEC. Investors should exercise their own judgment and consult with professional advisors before making investment decisions.
View Coeptis Therapeutics Holdings, Inc. Historical chart here
